Crescent Biopharma (CBIO) Competitors

$20.74 +0.51 (+2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$20.68 -0.06 (-0.31%)

As of 04:10 PM Eastern

CBIO vs. INVA, NVAX, ZBIO, LXRX, and MNKD

Should you buy Crescent Biopharma stock or one of its competitors? MarketBeat compares Crescent Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crescent Biopharma include Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), Lexicon Pharmaceuticals (LXRX), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to Innoviva?

Crescent Biopharma (NASDAQ:CBIO) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Innoviva has a net margin of 119.89% compared to Crescent Biopharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Innoviva	119.89%	33.33%	22.67%

Crescent Biopharma currently has a consensus target price of $28.00, indicating a potential upside of 35.00%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 61.18%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Crescent Biopharma had 4 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Crescent Biopharma and 1 mentions for Innoviva. Crescent Biopharma's average media sentiment score of 0.57 beat Innoviva's score of -0.35 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crescent Biopharma has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	52.73	-$153.94M	-$10.91	N/A
Innoviva	$411.33M	4.03	$271.17M	$6.01	3.74

Summary

Innoviva beats Crescent Biopharma on 9 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Novavax?

Crescent Biopharma (NASDAQ:CBIO) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Crescent Biopharma has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Novavax has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

Crescent Biopharma presently has a consensus price target of $28.00, indicating a potential upside of 35.00%. Novavax has a consensus price target of $12.13, indicating a potential upside of 31.65%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Crescent Biopharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Novavax has higher revenue and earnings than Crescent Biopharma. Novavax is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	52.73	-$153.94M	-$10.91	N/A
Novavax	$596.34M	2.54	$440.30M	-$0.58	N/A

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by company insiders. Comparatively, 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Crescent Biopharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Novavax	-14.73%	-14.82%	1.23%

In the previous week, Crescent Biopharma and Crescent Biopharma both had 5 articles in the media. Novavax's average media sentiment score of 0.62 beat Crescent Biopharma's score of 0.57 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Crescent Biopharma beats Novavax on 8 of the 15 factors compared between the two stocks.

How does Crescent Biopharma compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Zenas BioPharma has a beta of -0.61, indicating that its stock price is 161% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

75.2% of Crescent Biopharma shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Crescent Biopharma has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	119.76	-$377.74M	-$8.47	N/A
Crescent Biopharma	$10.84M	52.73	-$153.94M	-$10.91	N/A

Zenas BioPharma's return on equity of -99.99% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Crescent Biopharma	N/A	-103.44%	-88.19%

Zenas BioPharma presently has a consensus price target of $44.29, suggesting a potential upside of 133.45%. Crescent Biopharma has a consensus price target of $28.00, suggesting a potential upside of 35.00%. Given Zenas BioPharma's higher possible upside, equities research analysts clearly believe Zenas BioPharma is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

In the previous week, Zenas BioPharma had 14 more articles in the media than Crescent Biopharma. MarketBeat recorded 19 mentions for Zenas BioPharma and 5 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.57 beat Zenas BioPharma's score of -0.07 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zenas BioPharma and Crescent Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, suggesting a potential upside of 110.65%. Crescent Biopharma has a consensus target price of $28.00, suggesting a potential upside of 35.00%. Given Lexicon Pharmaceuticals' higher probable upside, equities analysts plainly believe Lexicon Pharmaceuticals is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Lexicon Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Crescent Biopharma	N/A	-103.44%	-88.19%

In the previous week, Crescent Biopharma had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Crescent Biopharma and 3 mentions for Lexicon Pharmaceuticals. Crescent Biopharma's average media sentiment score of 0.57 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has higher revenue and earnings than Crescent Biopharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$69.64M	13.78	-$50.34M	-$0.07	N/A
Crescent Biopharma	$10.84M	52.73	-$153.94M	-$10.91	N/A

Summary

Crescent Biopharma beats Lexicon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to MannKind?

MannKind (NASDAQ:MNKD) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

49.6% of MannKind shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MannKind has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Crescent Biopharma	N/A	-103.44%	-88.19%

MannKind presently has a consensus price target of $8.84, suggesting a potential upside of 161.65%. Crescent Biopharma has a consensus price target of $28.00, suggesting a potential upside of 35.00%. Given MannKind's higher probable upside, equities research analysts clearly believe MannKind is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

In the previous week, MannKind had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 8 mentions for MannKind and 5 mentions for Crescent Biopharma. MannKind's average media sentiment score of 0.92 beat Crescent Biopharma's score of 0.57 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has higher revenue and earnings than Crescent Biopharma. MannKind is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	2.99	$5.86M	-$0.07	N/A
Crescent Biopharma	$10.84M	52.73	-$153.94M	-$10.91	N/A

Summary

MannKind beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$571.59M	$3.02B	$6.40B	$12.30B
Dividend Yield	N/A	1.96%	2.79%	5.33%
P/E Ratio	-1.90	17.81	20.99	25.67
Price / Sales	52.73	584.24	579.56	98.72
Price / Cash	N/A	57.57	44.13	56.16
Price / Book	3.18	4.58	10.08	7.01
Net Income	-$153.94M	$74.99M	$3.56B	$335.38M
7 Day Performance	3.86%	-0.11%	4.91%	2.66%
1 Month Performance	-23.13%	-5.14%	1.51%	1.39%
1 Year Performance	N/A	34.05%	36.04%	35.43%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	2.4162 of 5 stars	$20.74 +2.5%	$28.00 +35.0%	N/A	$571.59M	$10.84M	N/A	50	News Coverage
INVA Innoviva	3.5489 of 5 stars	$21.73 -0.3%	$36.20 +66.6%	+17.2%	$1.61B	$411.33M	3.62	100
NVAX Novavax	2.0056 of 5 stars	$8.90 -0.3%	$12.13 +36.2%	+26.3%	$1.47B	$1.12B	N/A	1,990
ZBIO Zenas BioPharma	3.3012 of 5 stars	$17.84 +5.5%	$44.29 +148.2%	+81.4%	$1.07B	$10M	N/A	N/A	Analyst Revision
LXRX Lexicon Pharmaceuticals	1.9328 of 5 stars	$2.13 -0.5%	$4.55 +113.6%	+263.4%	$950.58M	$49.80M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, NVAX, ZBIO, LXRX, and MNKD

How does Crescent Biopharma compare to Innoviva?

Summary

How does Crescent Biopharma compare to Novavax?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Summary

How does Crescent Biopharma compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, NVAX, ZBIO, LXRX, and MNKD

How does Crescent Biopharma compare to Innoviva?

Do insiders & institutionals have more ownership in CBIO or INVA?

Is CBIO or INVA more profitable?

Do analysts recommend CBIO or INVA?

Does the media prefer CBIO or INVA?

Which has more volatility & risk, CBIO or INVA?

Which has better earnings and valuation, CBIO or INVA?

Summary

How does Crescent Biopharma compare to Novavax?

Which has more risk and volatility, CBIO or NVAX?

Do analysts prefer CBIO or NVAX?

Which has higher valuation and earnings, CBIO or NVAX?

Do institutionals and insiders have more ownership in CBIO or NVAX?

Is CBIO or NVAX more profitable?

Does the media prefer CBIO or NVAX?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Which has more volatility and risk, ZBIO or CBIO?

Do insiders and institutionals hold more shares of ZBIO or CBIO?

Which has better valuation & earnings, ZBIO or CBIO?

Is ZBIO or CBIO more profitable?

Do analysts prefer ZBIO or CBIO?

Does the media favor ZBIO or CBIO?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Do analysts rate LXRX or CBIO?

Which has more risk and volatility, LXRX or CBIO?

Is LXRX or CBIO more profitable?

Does the media favor LXRX or CBIO?

Do institutionals & insiders believe in LXRX or CBIO?

Which has better earnings and valuation, LXRX or CBIO?

Summary

How does Crescent Biopharma compare to MannKind?

Do institutionals and insiders believe in MNKD or CBIO?

Which has more volatility and risk, MNKD or CBIO?

Is MNKD or CBIO more profitable?

Do analysts rate MNKD or CBIO?

Does the media favor MNKD or CBIO?

Which has higher valuation and earnings, MNKD or CBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools